Systems and methods for delivery of a therapeutic agent

Patent metadata

Field	Value
Publication number	US-9498283-B2
Application number	US-201514601529-A
Country	US
Kind code	B2
Filing date	Jan 21, 2015
Priority date	Jul 22, 2005
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

First claim

What is claimed is:

1. A nerve modification device for altering nerve function in a bronchial airway of a patient, the nerve modification device comprising:
a main catheter body configured to extend though a trachea into the bronchial airway;
at least one energy applicator having at least one energy emitter configured to emit energy laterally relative to the main catheter body; and
a movable mechanism to move the at least one energy applicator laterally within the bronchial airway such that the at least one energy emitter contacts a first portion of a circumference of the airway wall,
wherein the nerve modification device is adapted to deliver energy from the at least one energy emitter to produce an energy field concentrated in a target region in the wall of the bronchial airway in a first lateral direction from the catheter body to alter nerve cells within the target region.

2. The nerve modification device of claim 1 , wherein the energy is at least one of x-ray energy, radiofrequency energy, DC current, AC current, microwave energy, and ultrasound energy.

3. The nerve modification device of claim 1 , wherein the at least one energy emitter comprises at least one electrode.

4. The nerve modification device of claim 3 , wherein the energy is RF energy.

5. The nerve modification device of claim 1 , wherein the at least one energy emitter comprises at least one ultrasound transducer.

6. The nerve modification device of claim 5 , wherein the energy is ultrasound energy.

7. The nerve modification device of claim 1 , wherein the movable mechanism comprises an expandable member coupled to the main catheter body, the expandable member being configured to expand to move the at least one energy emitter into contact with the first portion of the circumference of the wall.

8. The nerve modification device of claim 7 , wherein the expandable member is further configured to expand such that the expandable member engages a second portion of the circumference of the airway wall.

9. The nerve modification device of claim 8 , wherein the expandable member is expanded laterally in a second lateral direction from the catheter body opposite the first lateral direction.

10. A system for altering nerve function in a bronchial airway of a patient, the system comprising:
an intraluminal catheter configured to be positioned within a bronchial airway of a patient, the intraluminal catheter including
a main catheter body, and
a first energy emitter configured to emit energy laterally relative to the main catheter body;
a movable mechanism coupled to a distal end of the main catheter body, and configured to move the first energy emitter laterally within the bronchial airway such that the first energy emitter contacts a first portion of a circumference of the airway wall; and

an energy generator operably coupled to the first energy emitter and configured to activate the first energy emitter, thereby causing an energy field to be generated in a target region in the airway wall to alter nerve cells within the target region.

11. The system of claim 10 , wherein the first energy emitter is coupled to the movable mechanism, the system further comprising:
a second energy emitter operably coupled to the energy generator, the second energy emitter being configured to be positioned outside of the airway and remote from the target region, the target region being positioned between the first and second energy emitters such that activation of the first and second energy emitters by the energy generator produces the energy field between the first and second emitters and within the target region.

12. The system of claim 11 , wherein a placement of the first and second energy emitters relative to each other controls the size and/or intensity of the energy field.

13. The system of claim 10 , the system further comprising:
a second energy emitter operably coupled to the energy generator, and coupled to the movable mechanism relative to the first energy emitter such that an arrangement of the first and second energy emitters causes the energy field produced therefrom to be concentrated in a lateral direction from the main catheter body.

14. The system of claim 10 , a second energy emitter operably coupled to the energy generator, and coupled to the movable mechanism relative to the first energy emitter such that an arrangement of the first and second energy emitters causes the energy field produced therefrom to comprise a uniform energy field about the main catheter body.

15. The system of claim 10 , wherein the movable mechanism comprises an expandable member coupled to the main catheter body, the expandable member being configured to expand to move the first energy emitter into contact with a first portion of a circumference of the airway wall.

16. The system of claim 15 , wherein the expandable member is further configured to expand such that the expandable member engages a second portion of the circumference of the airway wall.

17. The system of claim 10 , wherein the energy is at least one of x-ray energy, radiofrequency energy, DC current, AC current, microwave energy, and ultrasound energy.

18. The system of claim 10 , wherein the first energy emitter comprises an electrode.

19. The system of claim 18 , wherein the energy is RF energy.

20. The system of claim 10 , wherein the first energy emitter comprises an ultrasound transducer.

Assignees

• Foundry Llc

Inventors

• Deem Mark E
• Gifford Hanson

Classifications

• A61K9/0021 Primary

  Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title

• A61P25/06

  Antimigraine agents · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title